4,5,6,7-四氢-2,1-苯并异恶唑-3-胺 | 13054-47-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4,5,6,7-四氢-2,1-苯并异恶唑-3-胺
• 英文名称: 4,5,6,7-tetrahydro-benzo[c]isoxazol-3-ylamine
• 英文别名: 4,5,6,7-Tetrahydro-benz[c]isoxazol-3-ylamin；3-amino-4,5,6,7-tetrahydro-2,1-benzisoxazole；3-Amino-4,5,6,7-tetrahydrocyclohexaisoxazol；3-Aminocyclohexisoxazol；5-Amino-3,4-tetramethylen-isoxazol；3,4-Cyclohexeno-5-aminoisoxazol；4,5,6,7-Tetrahydro-2,1-benzisoxazol-3-amine；4,5,6,7-tetrahydro-2,1-benzoxazol-3-amine
• CAS: 13054-47-2
• 化学式: C₇H₁₀N₂O
• mdl: MFCD06255135
• 分子量: 138.169
• InChiKey: CRGVRAUXLNRYKJ-UHFFFAOYSA-N

物化性质

• 熔点：
  130-132 °C(Solv: water (7732-18-5))
• 沸点：
  316.3±42.0 °C(Predicted)
• 密度：
  1.206±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  4,5,6,7-四氢-2,1-苯并异恶唑-3-胺 在 甲醇 、 sodium tetrahydroborate 、 乙醇 作用下， 生成 benzyl-(4,5,6,7-tetrahydro-benz[c]isoxazol-3-yl)-amine
  参考文献：
  名称：

  Kano; Makizumi, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1956, vol. 76, p. 1311,1312

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 硫酸 、 水 、 羟胺 作用下， 生成 4,5,6,7-四氢-2,1-苯并异恶唑-3-胺
  参考文献：
  名称：

  Derivatives of 5-(amino-phenylsulfonamido)-isoxazoles

  摘要：

  公开号：

  US02555614A1

文献信息

• Biphenylsulfonamide Endothelin Antagonists:  Structure−Activity Relationships of a Series of Mono- and Disubstituted Analogues and Pharmacology of the Orally Active Endothelin Antagonist 2‘-Amino-<i>N</i>- (3,4-dimethyl-5-isoxazolyl)-4‘-(2-methylpropyl)[1,1‘-biphenyl]-2-sulfonamide (BMS-187308)
  作者：Natesan Murugesan、Zhengxiang Gu、Philip D. Stein、Sharon Bisaha、Steve Spergel、Ravi Girotra、Ving G. Lee、John Lloyd、Raj N. Misra、Joan Schmidt、Arvind Mathur、Leslie Stratton、Yolanda F. Kelly、Eileen Bird、Tom Waldron、Eddie C.-K. Liu、Rongan Zhang、Helen Lee、Randy Serafino、Benoni Abboa-Offei、Parker Mathers、Mary Giancarli、Andrea Ann Seymour、Maria L. Webb、Suzanne Moreland、Joel C. Barrish、John T. Hunt

  DOI：10.1021/jm970872k

  日期：1998.12.1

  Substitution at the ortho position of N-(3,4-dimethyl-5-isoxazolyl) benzenesulfonamide led to the identification of the biphenylsulfonamides as a novel series of endothelin-A (ETA) selective antagonists. Appropriate substitutions on the pendant phenyl ring led to improved binding as well as functional activity. A hydrophobic group such as isobutyl or isopropoxyl was found to be optimal at the 4'-position

  N-（3,4-二甲基-5-异恶唑基）苯磺酰胺在邻位的取代导致将联苯磺酰胺鉴定为新型的内皮素-A（ETA）选择拮抗剂。苯环侧基上的适当取代导致改进的结合以及功能活性。发现疏水基团例如异丁基或异丙氧基在4'-位是最佳的。在2'-位引入氨基也导致改进的类似物。最佳的4'-异丁基取代基与2'-氨基官能团的结合提供了具有改善的ETA结合亲和力和功能活性的类似物（20，BMS-187308）。化合物20在抑制大鼠ET-1输注引起的升压作用方面也具有良好的口服活性。
• Sulfonamides and derivatives thereof that modulate the activity of
  申请人：Texas Biotechnology Corporation

  公开号：US05571821A1

  公开（公告）日：1996-11-05

  Sulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided. The sulfonamides have formula I: ##STR1## in which Ar.sup.1 is a 3- or 5-isoxazolyl and Ar.sup.2 is selected from among alkyl, including straight and branched chains, aromatic rings, fused aromatic rings and heterocyclic rings, including 5-membered heterocycles with one, two or more heteroatoms and fused ring analogs thereof and 6-membered rings with one, two or more heteroatoms and fused ring analogs thereof. Ar.sup.2 is preferably thiophenyl, furyl, pyrrolyl, naphthyl, and phenyl. Compounds in which Ar.sup.1 is a 4-halo-substituted isoxazole are more active than the corresponding alkyl-substituted compound and compounds in which Ar.sup.1 is substituted at this position with a higher alkyl tend to exhibit greater affinity for ET.sub.B receptors than the corresponding lower alkyl-substituted compound.

  磺胺类药物及使用这些磺胺类药物抑制内皮素肽与内皮素受体结合的方法是通过将磺胺类药物与受体接触来实现的。还提供了通过给予有效剂量的这些磺胺类药物或其前药来治疗内皮素介导的疾病的方法，这些药物能够抑制或增加内皮素的活性。这些磺胺类药物的化学式为I：##STR1## 其中Ar.sup.1是3-或5-异噁唑基，Ar.sup.2从烷基（包括直链和支链）、芳香环、融合芳香环和杂环中选择，包括含有一个、两个或更多杂原子的5元杂环及其融合环类似物，以及含有一个、两个或更多杂原子的6元环及其融合环类似物。Ar.sup.2最好是噻吩基、呋喃基、吡咯基、萘基和苯基。Ar.sup.1为4-卤代异噁唑基的化合物比相应的烷基取代化合物更活跃，而Ar.sup.1在这个位置被更高烷基取代的化合物倾向于表现出对ET.sub.B受体更大的亲和力，而不是相应的较低烷基取代的化合物。
• Sulfonamides and derivatives thereof that modulate the activity of endothelin
  申请人：TEXAS BIOTECHNOLOGY CORPORATION

  公开号：EP0870764A1

  公开（公告）日：1998-10-14

  A compound of the following formula: or a pharmaceutically acceptable salt thereof, where Ar2 is particularly phenyl, biphenyl or naphthyl and R1 and R2 are as defined herein, useful in the modulation of the activity of endothelin.

  下式化合物 或其药学上可接受的盐，其中 Ar2 特别是苯基、联苯基或萘基，R1 和 R2 如本文所定义，可用于调节内皮素的活性。
• Discovery and Structure-Activity Relationships of Sulfonamide ETA-Selective Antagonists
  作者：Philip D. Stein、David M. Floyd、Sharon Bisaha、Joyce Dickey、Ravindar N. Girotra、Jack Z. Gougoutas、Michael Kozlowski、Ving G. Lee、Eddie C.-K. Liu

  DOI：10.1021/jm00008a013

  日期：1995.4

  Random screening of compounds in an ETA receptor binding assay led to the discovery of a class of benzenesulfonamide ligands. Optimization led to the development of 5-amino-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamides which were functional antagonists. Structural features which were important to activity included a 1,5-substitution pattern on the naphthalene ring; a sulfonamide NH with a pK value < 7; an amine, preferably with alkyl substituents, at the 5-position; and methyl groups on both the 3- and 4-positions of the isoxazole.
• Eine neue Synthese von 3-Aminoisoxazolen1 und 3-Aminoisoxazolinen mit Hilfe von N-Hydroxyharnstoff
  作者：W. Kl�tzer、H. Bretschneider、E. Fitz、R. Reiner、G. Bader

  DOI：10.1007/bf00908555

  日期：——